A detailed history of Addison Advisors LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Addison Advisors LLC holds 4,298 shares of BMY stock, worth $228,610. This represents 0.06% of its overall portfolio holdings.

Number of Shares
4,298
Previous 4,017 7.0%
Holding current value
$228,610
Previous $217,000 17.97%
% of portfolio
0.06%
Previous 0.08%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$40.25 - $52.99 $11,310 - $14,890
281 Added 7.0%
4,298 $178,000
Q1 2024

May 06, 2024

BUY
$47.98 - $54.4 $7,964 - $9,030
166 Added 4.31%
4,017 $217,000
Q4 2023

Feb 02, 2024

BUY
$48.48 - $57.85 $35,438 - $42,288
731 Added 23.43%
3,851 $197,000
Q3 2023

Nov 07, 2023

BUY
$57.89 - $64.73 $11,114 - $12,428
192 Added 6.56%
3,120 $181,000
Q2 2023

Aug 03, 2023

SELL
$63.71 - $70.74 $1,210 - $1,344
-19 Reduced 0.64%
2,928 $187,000
Q1 2023

May 09, 2023

BUY
$65.71 - $74.53 $1,314 - $1,490
20 Added 0.68%
2,947 $204,000
Q4 2022

Feb 07, 2023

SELL
$68.48 - $81.09 $50,127 - $59,357
-732 Reduced 20.01%
2,927 $210,000
Q3 2022

Oct 28, 2022

BUY
$0.13 - $76.84 $9 - $5,686
74 Added 2.06%
3,659 $260,000
Q2 2022

Aug 04, 2022

SELL
$72.62 - $79.98 $10,675 - $11,757
-147 Reduced 3.94%
3,585 $276,000
Q1 2022

Apr 29, 2022

BUY
$61.48 - $73.72 $33,691 - $40,398
548 Added 17.21%
3,732 $273,000
Q4 2021

Jan 31, 2022

BUY
$53.63 - $62.52 $34,698 - $40,450
647 Added 25.5%
3,184 $199,000
Q3 2021

Nov 08, 2021

BUY
$59.17 - $69.31 $710 - $831
12 Added 0.48%
2,537 $150,000
Q2 2021

Jul 29, 2021

SELL
$61.91 - $67.42 $7,738 - $8,427
-125 Reduced 4.72%
2,525 $169,000
Q4 2020

Feb 02, 2021

BUY
$57.74 - $65.43 $153,011 - $173,389
2,650 New
2,650 $164,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Addison Advisors LLC Portfolio

Follow Addison Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Addison Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Addison Advisors LLC with notifications on news.